ELUT vs. GNFT, SLDB, PSTX, BDTX, CRBU, CADL, IPSC, ADAP, MGX, and ZURA
Should you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Genfit (GNFT), Solid Biosciences (SLDB), Poseida Therapeutics (PSTX), Black Diamond Therapeutics (BDTX), Caribou Biosciences (CRBU), Candel Therapeutics (CADL), Century Therapeutics (IPSC), Adaptimmune Therapeutics (ADAP), Metagenomi (MGX), and Zura Bio (ZURA). These companies are all part of the "biological products, except diagnostic" industry.
Genfit (NASDAQ:GNFT) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends.
Genfit has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Elutia has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
Genfit has a net margin of 0.00% compared to Genfit's net margin of -164.45%.
In the previous week, Genfit and Genfit both had 2 articles in the media. Genfit's average media sentiment score of 1.44 beat Elutia's score of 1.26 indicating that Elutia is being referred to more favorably in the news media.
Genfit has higher revenue and earnings than Elutia.
Genfit received 59 more outperform votes than Elutia when rated by MarketBeat users. However, 100.00% of users gave Elutia an outperform vote while only 68.09% of users gave Genfit an outperform vote.
2.2% of Genfit shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 4.2% of Genfit shares are held by company insiders. Comparatively, 40.8% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Genfit presently has a consensus price target of $11.00, suggesting a potential upside of 112.36%. Elutia has a consensus price target of $5.00, suggesting a potential upside of 53.85%. Given Elutia's higher possible upside, research analysts clearly believe Genfit is more favorable than Elutia.
Summary
Genfit beats Elutia on 8 of the 13 factors compared between the two stocks.
Get Elutia News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
